Background: Gaucher disease (GD) and primary myelofibrosis (PMF) share similar clinical and laboratory features, such as cytopenia, hepatosplenomegaly, and marrow fibrosis, often resulting in a misdiagnosis. Case Report: We report here the case of a young woman with hepatosplenomegaly, leukopenia, and thrombocytopenia. Based on bone marrow (BM) findings and on liver biopsy showing extramedullary hematopoiesis, an initial diagnosis of PMF was formulated. The patient refused stem cell transplantation from an HLAidentical sibling. Low-dose melphalan was given, without any improvement. Two years later, a BM evaluation showed Gaucher cells. Low glucocerebrosidase and high chitotriosidase levels were indicative for GD. Molecular analysis revealed N370S/complex I mutations. Enzyme replacement therapy with imiglucerase was commenced, resulting in clinical and hematological improvements. Due to an unexpected and persistent organomegaly, PMF combined with GD were suspected. JAK2 V617F , JAK2 exon 12, MPL, calreticulin, and exon 9 mutations were negative, and BM examination showed no marrow fibrosis. PMF was excluded. Twenty years after starting treatment, the peripheral cell count and liver size were normal, whereas splenomegaly persisted. Conclusion: In order to avoid a misdiagnosis, a diagnostic algorithm for patients with hepatosplenomegaly combined with cytopenia is suggested.
Introduction
Gaucher disease (GD), a rare autosomal recessive disorder, and primary myelofibrosis (PMF), a rare clonal myeloproliferative neoplasm, may present similar features, such as thrombocytopenia, anemia, leukopenia, splenomegaly, and marrow fibrosis, resulting in a diagnostic challenge.
Case Report
In November 1994, a 32-year-old woman, with a clinical history of nontraumatic bone fractures (femur and tibia) at the age of 15 years with unknown causes, was referred to our center due to hepatosplenomegaly, leukopenia, and thrombocytopenia. The patient had been asymptomatic until 1990 when hepatosplenomegGaucher Disease and Myelofibrosis aly was found during her fourth pregnancy (she had previously had 3 spontaneous abortions). At that time, the peripheral blood (PB) cell count, serum proteins and albumin, and kidney and liver function were in the normal range, except for mild liver enzyme abnormalities and thrombocytopenia. A liver biopsy, performed during the caesarian section, revealed extramedullary hematopoiesis. Despite this finding, the patient was referred to our center only in 1994, with a suspected diagnosis of PMF. On admission, clinical examinations revealed hepatomegaly and palpable splenomegaly. The full blood count showed thrombocytopenia (platelets 78 ×10 9 /L) and leukopenia (leukocytes 3.2 ×10 9 /L with a normal differential count) with an Hb level of 11.1 g/dL; the serum ferritin level was 566 μg/L. An abdominal ultrasonography confirmed the hepatomegaly (transversal diameter 146 mm) and splenomegaly (diameters 246 × 112 × 104 mm). Cytogenetic analysis revealed an inherited translocation t(6,13) without clinical significance. A bone marrow (BM) biopsy showed a decreased cellularity, normal megakaryocytic proliferation with atypia (lobulated and naked nuclei), and a significant increase of reticulin fibers and collagen deposition. A diagnosis of PMF was made. Given the young age of the patient and the availability of an HLA-matched sibling, a stem cell transplantation was considered but the patient refused. Lowdose melphalan was then given. Two years after starting treatment, the persisting thrombocytopenia, leukopenia, and hepatosplenomegaly led us to perform a BM revaluation. Surprisingly, histiocyte clusters CD68R+ (PAS/PAS-D+) suggestive of Gaucher cells and an increased marrow cellularity, normal granulopoiesis, erythropoietic and megakaryocytic dysplasia, and significant reticulin and collagen fibrosis were found. Low-dose melphalan was stopped. Low glucocerebrosidase activity and a high value of chitotriosidase were suggestive for GD. Molecular analysis revealed N370S/complex I mutations, allowing a diagnosis of nonneuropathic type I GD. A further comprehensive assessment of all potentially affected organ systems was performed. A full blood count was as follows: platelets 71 ×10 9 /L, leukocytes 3.2 ×10 9 /L, Hb 10.5 g/dL, and ultrasonography-confirmed increased hepatomegaly and unchanged splenomegaly. Skeletal evaluation (X-rays and dexa mineralometry) excluded bone involvement. In June 1997, enzyme replacement therapy (ERT) with imiglucerase at a monthly dose of 30 U/ kg was started. One year later, due to persistent pancytopenia and unchanged hepatosplenomegaly, the ERT dose was increased to 60 U/kg/month. The platelet and leukocyte counts, as well as the Hb level, reached the normal range 6 years after starting treatment. Subsequently, a persistent hepatosplenomegaly suggested PMF combined with GD. Human androgen receptor assay PCR analysis [1] showed a polyclonal hematopoiesis. In February 2008, the JAK2 V617F , JAK2 exon 12, and MPL mutations were analyzed in PB cells as previously described [2] . No mutations of the investigated genes were found. The patient continued ERT at a dose of 60 U/ kg/month. In 2013, calreticulin (CALR) exon 9 analysis was carried out without any evidence of mutations [3, 4] . At this time, the PB values were normal, whereas splenomegaly and mild hepatomegaly persisted. An additional BM biopsy was performed. The medullary framework was characterized by a normal hematopoiesis, presence of scattered Gaucher cells, and absence of fibrosis. A diagnosis of PMF was excluded. The patient continued ERT at the same dose obtaining a progressive reduction of the hepatosplenomegaly. At the last follow-up in 2017, 20 years after starting treatment, the PB cell count was normal; ultrasonography and MRI revealed a mild splenomegaly (diameters 140 × 100 × 90 mm) and a normal liver size.
Discussion
GD and PMF share many clinical and laboratory features to such an extent that GD can be easily missed as a possible diagnosis. In order to diagnose PMF, a BM biopsy is essential. However, a BM biopsy is also indicated in GD when the differential diagnosis with a hematologic disease is necessary. In the case presented here, the first BM biopsy confirmed the suspicion of PMF because of a striking marrow framework of myelofibrosis without Gaucher cells. However, the second BM biopsy showed the presence of both fibrosis and lipid-storage macrophages, suggesting a diagnosis of GD, which was confirmed by assessing the glucocerebrosidase activity and by molecular analysis. In both PMF and GD there is an activation of proinflammatory cytokine pathways that could have an important role in the modification of the BM microenvironment leading to the development of marrow fibrosis. Genetic and epigenetic abnormalities, which can be found in PMF, play a role in the defective clonal hematopoietic stem cell proliferation, with the release of several cytokines in the marrow microenvironment. In GD, a malfunction of the lipid-storage macrophages, namely Gaucher cells, induces an increased expression of proinflammatory cytokines leading to a marrow fibrosis [5] . The framework from the first biopsy was due to the activation of many proinflammatory cytokines by unidentified Gaucher cells, while BM framework of the last biopsy was the result of the ERT activity on the reticulin and collagen fibers.
The assessment of somatic-acquired JAK2V617F, JAK2 exon 12, MPL, and CALR gene mutations in the PB has recently become a mandatory diagnostic tool in myeloproliferative neoplasm, including PMF, as the presence of one of these mutations is a major criterion for PMF according to the 2016 WHO classification [6] . In conclusion, the diagnosis of GD should be considered in the presence of a long-lasting splenomegaly and hepatomegaly combined with cytopenia. In order to avoid future misdiagnoses, the use of a diagnostic algorithm for patients with combined hepatosplenomegaly and cytopenia is recommended (Fig. 1) .
